Pembrolizumab & Melanoma (cutaneous)

FDA status:

In the context of Pembrolizumab & Melanoma (cutaneous), pembrolizumab received its first FDA approval in 2014 for unresectable or metastatic Melanoma (cutaneous), initially in patients previously treated with ipilimumab (and, if BRAF‑mutant, a BRAF inhibitor) (1, 2, 3, 4). The indication subsequently expanded to first‑line treatment of unresectable or metastatic melanoma regardless of BRAF status, and to adjuvant therapy for resected high‑risk stage III and later stage IIB–IIC cutaneous melanoma (1, 5, 6), FDA h…